| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
The receptor for advanced glycation end-products (RAGE) is a multi-ligand receptor which belongs to the immunoglobulin superfamily. RAGE is reported to be involved in various inflammatory disorders, however, studies that address the role of RAGE in allergic airway disease are inconclusive. RAGE sufficient (RAGE+/+) and RAGE deficient (RAGE-/-) mice were sensitized to ovalbumin (OVA), and airway responses were monitored after OVA challenge. RAGE-/- mice showed reduced eosinophilic inflammation and goblet cell metaplasia, lower T helper type 2 (Th2) cytokine production from spleen and peribronchial lymph node mononuclear cells, and lower numbers of group 2 innate lymphoid cells (ILC2s) in the lung compared to RAGE+/+ mice following sensitization and challenge. Thus, manipulating RAGE represents a novel therapeutic target in controlling allergic airway responses.
|
